阿立哌唑
分裂情感障碍
利培酮
安慰剂
心理学
阳性与阴性症状量表
精神分裂症(面向对象编程)
精神科
焦虑
氟哌啶醇
人口
内科学
医学
精神病
临床心理学
多巴胺
替代医学
病理
环境卫生
作者
Philip G. Janicak,Ira D. Glick,Stephen R. Marder,David T. Crandall,Robert D. McQuade,Ronald N. Marcus,James M. Eudicone,Sheila Assunção-Talbott
摘要
Article AbstractObjective: To evaluate the efficacy of aripiprazole across a range of symptoms--positive, negative, disorganized thought, depression/anxiety, and hostility--in schizophrenia and schizoaffective disorder.Method: Pooled data were analyzed from 5 short-term, double-blind, multicenter studies (published between 1997 and 2007) involving patients hospitalized with acute exacerbation of schizophrenia (5 studies) or schizoaffective disorder (2 studies) and randomly assigned to aripiprazole (N = 875), haloperidol (N = 193), risperidone (N = 95), or placebo (N = 406). Aripiprazole doses ranged from 2 to 30 mg/day. Patients receiving the ineffective 2-mg dose were excluded from the primary analyses presented here. Factor analysis of Positive and Negative Syndrome Scale (PANSS) data was used to evaluate changes from baseline with aripiprazole on 5 symptom factors--positive, negative, disorganized thought, depression/anxiety, and hostility--in 2 population subsets--schizophrenia and schizoaffective disorder. Pairwise comparisons were made as follows for schizophrenia: aripiprazole versus placebo in all 5 studies; aripiprazole, haloperidol, and placebo in 3 studies; and aripiprazole, risperidone, and placebo in 1 study. Patients with schizoaffective disorder in 2 studies were included in the comparison of aripiprazole and placebo.Results: Aripiprazole was significantly better than placebo in improving all 5 PANSS factor scores from baseline (each pConclusion: In this large dataset, aripiprazole was associated with improvements in a broad range of symptom domains in the short-term treatment of schizophrenia and schizoaffective disorder.
科研通智能强力驱动
Strongly Powered by AbleSci AI